Oxyresveratrol Alleviates Irinotecan-Induced Diarrhea and Enhances Antitumor Effects in Colorectal Cancer

Overview

Journal Drug Des Devel Ther

Specialty Pharmacology

Date 2025 Jan 1

PMID 39741919

Authors

Xing Yang

Hengxiang Yu

Liming Zhou

Affiliations

Soon will be listed here.

Abstract

Objective: To investigate whether oxyresveratrol (OXY) can alleviate irinotecan (CPT-11)-induced intestinal toxicity and whether the combination of these two drugs can enhance the inhibition of colorectal cancer cells.

Methods: The CCK-8 assay was used to assess the inhibitory effects of OXY and CPT-11, both as monotherapies and in combination, on the proliferation of colorectal cancer cell lines HCT116 and SW620. Mice were grouped (8/mice/group) into: control, CPT-11, low-dose OXY+CPT-11, high-dose OXY+CPT-11. Each trial was conducted as an independent experiment. A mouse diarrhea model induced by CPT-11 was established to observe the general condition, diarrhea score, spleen and colon of each group of mice. Bioinformatics tools were employed to predict the targets of OXY and CPT-11, followed by GO and KEGG enrichment analyses.

Results: CPT-11 inhibited the growth of colorectal cancer cells in a dose-dependent manner, and OXY combined treatment had additive effects. Mice in the CPT-11 group experienced significant weight loss and severe diarrhea, while the co-administration of OXY alleviated these adverse effects. Bioinformatics analysis revealed that the targets of OXY and CPT-11 were enriched in pathways such as PI3K/Akt and cell cycle, suggesting that the combination therapy might exert a synergistic effect by modulating these pathways.

Conclusion: The combination of OXY and CPT-11 enhances the inhibitory effect on colorectal tumor cells and reduces the intestinal toxicity induced by CPT-11. This study provides a novel strategy for colorectal cancer chemotherapy.

References

OConnell E, Reynolds I, Salvucci M, McNamara D, Burke J, Prehn J . Mucinous and non-mucinous colorectal cancers show differential expression of chemotherapy metabolism and resistance genes. Pharmacogenomics J. 2021; 21(4):510-519. DOI: 10.1038/s41397-021-00229-5. View

Yeom J, Ma S, Kim J, Lim Y . Oxyresveratrol Ameliorates Dextran Sulfate Sodium-Induced Colitis in Rats by Suppressing Inflammation. Molecules. 2021; 26(9). PMC: 8124641. DOI: 10.3390/molecules26092630. View

Hwang D, Jo H, Ma S, Lim Y . Oxyresveratrol stimulates mucin production in an NAD-dependent manner in human intestinal goblet cells. Food Chem Toxicol. 2018; 118:880-888. DOI: 10.1016/j.fct.2018.06.039. View

Zhang W, Liu Y, Ge M, Jing J, Chen Y, Jiang H . Protective effect of resveratrol on arsenic trioxide-induced nephrotoxicity in rats. Nutr Res Pract. 2014; 8(2):220-6. PMC: 3988513. DOI: 10.4162/nrp.2014.8.2.220. View

Hwang D, Jo H, Hwang S, Kim J, Kim I, Lim Y . Conditioned medium from LS 174T goblet cells treated with oxyresveratrol strengthens tight junctions in Caco-2 cells. Biomed Pharmacother. 2016; 85:280-286. DOI: 10.1016/j.biopha.2016.11.022. View

Pereira V, Melo A, Assis-Junior E, V T Wong D, Brito G, Almeida P . A new animal model of intestinal mucositis induced by the combination of irinotecan and 5-fluorouracil in mice. Cancer Chemother Pharmacol. 2015; 77(2):323-32. DOI: 10.1007/s00280-015-2938-x. View

Erdem Z, Schwarz S, Drev D, Heinzle C, Reti A, Heffeter P . Irinotecan Upregulates Fibroblast Growth Factor Receptor 3 Expression in Colorectal Cancer Cells, Which Mitigates Irinotecan-Induced Apoptosis. Transl Oncol. 2017; 10(3):332-339. PMC: 5367848. DOI: 10.1016/j.tranon.2017.02.004. View

Yuan L, Zhou M, Huang D, Wasan H, Zhang K, Sun L . Resveratrol inhibits the invasion and metastasis of colon cancer through reversal of epithelial‑ mesenchymal transition via the AKT/GSK‑3β/Snail signaling pathway. Mol Med Rep. 2019; 20(3):2783-2795. PMC: 6691253. DOI: 10.3892/mmr.2019.10528. View

Kaliannan K, Donnell S, Murphy K, Stanton C, Kang C, Wang B . Decreased Tissue Omega-6/Omega-3 Fatty Acid Ratio Prevents Chemotherapy-Induced Gastrointestinal Toxicity Associated with Alterations of Gut Microbiome. Int J Mol Sci. 2022; 23(10). PMC: 9140600. DOI: 10.3390/ijms23105332. View

10.

Lin T, Lin W, Chou Y, Nagabhushanam K, Ho C, Pan M . Oxyresveratrol inhibits human colon cancer cell migration through regulating epithelial-mesenchymal transition and microRNA. Food Funct. 2021; 12(20):9658-9668. DOI: 10.1039/d1fo01920a. View

11.

Breuss J, Atanasov A, Uhrin P . Resveratrol and Its Effects on the Vascular System. Int J Mol Sci. 2019; 20(7). PMC: 6479680. DOI: 10.3390/ijms20071523. View

12.

Likhitwitayawuid K . Oxyresveratrol: Sources, Productions, Biological Activities, Pharmacokinetics, and Delivery Systems. Molecules. 2021; 26(14). PMC: 8307110. DOI: 10.3390/molecules26144212. View

13.

Li R, Song Y, Ji Z, Li L, Zhou L . Pharmacological biotargets and the molecular mechanisms of oxyresveratrol treating colorectal cancer: Network and experimental analyses. Biofactors. 2019; 46(1):158-167. DOI: 10.1002/biof.1583. View

14.

Pencreach E, Guerin E, Nicolet C, Lelong-Rebel I, Voegeli A, Oudet P . Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-inducible factor-1alpha axis. Clin Cancer Res. 2009; 15(4):1297-307. DOI: 10.1158/1078-0432.CCR-08-0889. View

15.

Deng H, He X, Xu Y, Hu X . Oxyresveratrol from Mulberry as a dihydrate. Acta Crystallogr Sect E Struct Rep Online. 2012; 68(Pt 5):o1318-9. PMC: 3344458. DOI: 10.1107/S1600536812014018. View

16.

Crea F, Giovannetti E, Cortesi F, Mey V, Nannizzi S, Gallegos Ruiz M . Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines. Mol Cancer Ther. 2009; 8(7):1964-73. DOI: 10.1158/1535-7163.MCT-09-0027. View

17.

Liu Y, Ren W, Bai Y, Wan L, Sun X, Liu Y . Oxyresveratrol prevents murine H22 hepatocellular carcinoma growth and lymph node metastasis via inhibiting tumor angiogenesis and lymphangiogenesis. J Nat Med. 2018; 72(2):481-492. DOI: 10.1007/s11418-018-1173-2. View

18.

Reita D, Bour C, Benbrika R, Groh A, Pencreach E, Guerin E . Synergistic Anti-Tumor Effect of mTOR Inhibitors with Irinotecan on Colon Cancer Cells. Cancers (Basel). 2019; 11(10). PMC: 6826690. DOI: 10.3390/cancers11101581. View

19.

Nunes S, Danesi F, Del Rio D, Silva P . Resveratrol and inflammatory bowel disease: the evidence so far. Nutr Res Rev. 2017; 31(1):85-97. DOI: 10.1017/S095442241700021X. View

20.

Zhang Y, Zhang X, Ding Y, Kong Y, Zhu X, Li P . Distinct time trends in colorectal cancer incidence in countries with SDI levels from 1990 to 2019: an age-period-cohort analysis for the Global Burden of Disease 2019 study. Front Public Health. 2024; 12:1370282. PMC: 11150799. DOI: 10.3389/fpubh.2024.1370282. View